First Wave BioPharma, Inc. (FWBI)
NASDAQ: FWBI · IEX Real-Time Price · USD
2.740
+0.010 (0.37%)
At close: Apr 26, 2024, 4:00 PM
2.820
+0.080 (2.92%)
After-hours: Apr 26, 2024, 5:37 PM EDT
First Wave BioPharma Stock Forecast
FWBI's stock price has decreased by -95.19% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for FWBI stock has a target of 36, which predicts an increase of 1,213.87% from the current stock price of 2.74.
Analyst Consensus: Buy
* Price targets were last updated on Mar 15, 2024.
Analyst Ratings
The average analyst rating for FWBI stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Mar 25, 2024 |
| Roth MKM | Roth MKM | Strong Buy Maintains $40 → $36 | Strong Buy | Maintains | $40 → $36 | +1,213.87% | Mar 15, 2024 |
| Roth MKM | Roth MKM | Strong Buy Maintains $11 → $40 | Strong Buy | Maintains | $11 → $40 | +1,359.85% | Jan 3, 2024 |
| Roth MKM | Roth MKM | Strong Buy Reiterates $220 | Strong Buy | Reiterates | $220 | +7,929.20% | Sep 19, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 14, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.67
from -47.88
EPS Next Year
-1.58
from -3.67
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | 24.0M | 64.0M |
| Avg | n/a | n/a | n/a | 23.3M | 62.2M |
| Low | n/a | n/a | n/a | 22.4M | 59.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 174.8% |
| Avg | - | - | - | - | 166.9% |
| Low | - | - | - | - | 156.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.89 | -1.63 | -2.36 |
| Avg | -3.67 | -1.58 | -2.30 |
| Low | -5.28 | -1.52 | -2.21 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.